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INTRODUCTION
Gastric or esophageal variceal bleeding has been a major
cause of deaths in liver cirrhosis (1). Among the treatment
modalities for gastric and esophageal variceal bleeding, medical
treatment such as glypressin etc. or other palliative treatment
using the S-B tube, whose hemostatic effect is not persistent
(2, 3), sclerotherapy, and band ligation by endoscopy show a
high rebleeding rate primarily because the portal pressure is not
decreased (4, 5). Surgical porto-systemic shunt can decrease
the portal venous pressure, however, is limited by its high
surgical mortality (6-8).
Since percutaneous decompression of portal hypertension
was reported by Rosch et al. in 1969, transjugular intrahepatic
portosystemic shunt (TIPSS) has been known as an effective
treatment method (9). 
Therefore, we performed this study to determine the factors
contributing to the survival time and rebleeding rate after
TIPSS.
MATERIALS AND METHODS 
Subject
One hundred and fifty-five patients who had undergone
TIPSS between September 1991 to March 2001 were selected
retrospectively. Endoscopic treatment was ineffective or tech-
nically very difficult in all cases. One hundred and twenty-six
cases among them had gastric variceal bleeding and 29 cases
had esophageal variceal bleeding. Endoscopic examination
showed that 23 cases had only esophageal varices, 24 cases only
gastric varices, and the other 108 cases had both esophageal
and gastric varices. Twenty-seven cases had active bleeding, 21
cases from gastric varices and 6 cases from esophageal varices.
The mean age of the patients was 53 yr (18-78 yr), and 123
cases were male and 32 cases were female. Thirty-one cases
were the Child-Pugh classification A, 88 cases were B, and
36 cases were C.
The causes of liver cirrhosis were alcohol in 60 cases, HBV
in 75 cases, HCV in 9 cases, mixed type of HBV and HCV
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Prognostic Factors of the Long-Term Survival after Transjugular 
Intrahepatic Portosystemic Shunt in the Treatment of Gastric and
Esophageal Variceal Bleeding
Transjugular intrahepatic portosystemic shunt (TIPSS) is a promising method of
treatment for gastric or esophageal variceal bleeding. This study was performed to
determine the prognostic factors contributing to the survival of patients after TIPSS
for gastric or esophageal variceal bleeding. One hundred and fifty-five patients who
underwent TIPSS between September 1991 and March 2001 were followed up
by clinical examination, upper gastrointestinal endoscopy, and Duplex sonography.
The mean portohepatic pressure gradient prior to TIPSS was 20.5±9.93 mmHg
and dropped to 10.7±6.62 mmHg after TIPSS (p<0.001). The cumulative survival
rate was 75.1% at 6 months, 66.6% at 1 yr, 58.4% at 2 yr, and 38.1% at 5 yr. Sur-
vival after TIPSS was inversely related to the Child-Pugh classification (p<0.05).
The rebleeding rate was 18.3% at 6 months, 21.0% at 1 yr, 32.8% at 2 yr, and
53.1% at 5 yr. The causes of deaths were hepatic failure (53.5%), recurrent variceal
bleeding (11.6%), pneumonia (4.6%), sepsis (3.5%), hepatic encephalopathy (2.3%),
and unknown (17.4%). Multivariate analysis (Cox proportional hazard model)
revealed that the Child-Pugh classification and age were statistically significant
independent prognostic factors. In conclusion, TIPSS is an effective method of
treatment for variceal bleeding in cases where other treatment modalities including
endoscopic therapy are unsuccessful and the most important prognostic factors
are preprocedural hepatic reserve (Child-Pugh class) and age. 
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Accepted : 29 August 2002in 1 case, cholestatic liver disease in 2 cases, glycogen storage
disease in 1 case, and idiopathic in 7 cases.
Seventy-five cases (48.4%) had a previous history of gastric
or esophageal variceal bleeding. Thirty-eight cases among them
had a history of endoscopic sclerotherapy or band ligation or
percutaneous esophageal variceal embolization and the others
received conservative treatment for bleeding. The mean hos-
pitalization duration of the cases was 19 days and the mean
post-TIPSS follow-up time was 116±106.2 weeks.
Diagnostic studies before TIPSS and follow-up 
We confirmed the site of bleeding and the severity of varices
by endoscopy. The patients’ general status was evaluated by
blood tests including liver function test, Hb, platelet count,
prothrombin time, ammonia, Na
+, K
+, BUN, and creatinine,
and ultrasonogram was done before procedure to detect hep-
atocellular carcinoma or portal vein thrombosis. 
After procedure, we repeated endoscopy to evaluate the state
of hemostasis, rebleeding, and the size of varices, and we repeat-
ed blood tests including liver function test, blood ammonia
to check side effects or complication, especially concerning the
development of hepatic encephalopathy.
After discharge, we followed up clinical progress and per-
formed blood tests and upper gastrointestinal endoscopy every
three to six months.
TIPSS 
After puncture and catheterization to the internal jugular
vein at the right supraclavicular site, we took a hepatic venous
angiogram to decide the shunt site from hepatic vein to portal
vein. After puncture of portal vein, we checked the portal
pressure, compared with the hepatic venous pressure, and
performed a portal venous angiogram. We detected the varices
by portal angiogram, dilated the puncture site of portal vein
by a balloon catheter, put a metal stent, and formed a porto-
hepatic shunt. After shunt formation, we checked the decrease
of the portal pressure and confirmed disappearance of the varices
and shunt flow by portal angiogram.
Statistics
Reliablility of each clinical value was checked by Student’s
t-test, one-way ANOVA and chi-square test. The survival rate
was analysed by the survival curves by the Kaplan-Meier
method (10), and the difference between each group’s survival
rate was proved by log-rank test and Wilcoxon test. 
To determine the factors affecting the life expectancy and
the time of rebleeding, we performed the log-rank test and
Cox-proportional hazard model.
RESULTS
Effects of TIPSS 
Establishment of the shunt was successful in all cases, and
the porto-hepatic pressure gradient was decreased by average
9.8±5.54 mmHg, from 20.5±9.93 mmHg before TIPSS
to 10.7±6.62 mmHg after the procedure (p<0.001) (Fig. 1).
In 108 cases for which follow-up endoscopy was performed
within 14 days after TIPSS, 19 cases (17.6%) had no varices,
79 cases (73.1%) showed a decreased size of the esophageal
and gastric varices, and 10 cases (9.3%) had no change. 
Survival rate and factors affecting the survival rate
According to the analysis of survival rate by the Kaplan-
Meier method, the mean survival time after TIPSS was 186.7
±14.9 weeks. The cumulative survival rate was 75.1% at 6
months after TIPSS, 66.6% at 1 yr, 58.4% at 2 yr, and 38.1%
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Fig. 1. Decreased porto-hepatic pressure gradient after TIPSS.
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Fig. 2. Cumulative survival rate after TIPSS.
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at 5 yr (Fig. 2).
The univariate analysis showed that the male sex, older age,
the Child-Pugh class C, and the less decrease of portal venous
pressure after TIPSS were associated with a significantly lower
survival rate. However, in the multivariate analysis, the Child-
Pugh classification was the only significant factor affecting
the survival rate. 
The mean survival rates by the Child-Pugh classification
were 225.0±27.6 weeks in A, 192.5±19.8 weeks in B, and
53.6±95 weeks in C; there were statistically significant dif-
ferences between the groups (p<0.05) (Fig. 3).
The age of patients at the time of procedure was classified
into 5 groups ; 39 yr or less, 40-49 yr, 50-59 yr, 60-69 yr, and
70 yr or more. The mean survival times of the age groups were
147.0±16.1 weeks, 127.5±14.1 weeks, 208.9±24.5 weeks,
84.9±10.6 weeks, and 21.2±9.9 weeks, respectively. There
were significant differences between the groups (p<0.0001)
(Fig. 4 and Table 2).
Rebleeding rate and factors related with rebleeding
Fifty cases (32.2%) experienced rebleeding after TIPSS. The
mean time of rebleeding after TIPSS was 167.9±10.7 weeks.
The cumulative rebleeding rates were 18.3% at 6 months,
21.0% at 1 yr, 32.8% at 2 yr, and 53.1% at 5 yr after TIPSS.
The result of univariate analysis showed a significantly
higher rebleeding rate in male patients and in cases with a
history of more frequent bleeding before TIPSS. But in the
multivariate analysis, there was no significant factor affecting
the rebleeding rate. In 43 out of 50 cases of rebleeding, Doppler
ultrasonogram was done and the state of shunt flow was
checked. Twenty cases (46.5%) had shunt obstruction and 12
cases (27.9%) had shunt stenosis. The shunt flow was kept
well in 11 cases.
Among 50 cases of rebleeding, 24 cases underwent a second
TIPSS and 8 patients expired during resuscitation. In 2 cases,
bleeding was controlled by band ligation and 6 patients expired
due to rebleeding after control of the first rebleeding episode.
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Fig. 4. Cumulative survival rates after TIPSS by age (yr) (p<0.0001).
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Fig. 3. Cumulative survival rates after TIPSS by Child-Pugh class
A, B, and C (p=0.0118).
Mean age (range) (yr) 53 (18-78)
Sex (Male/Female) 123/32
Etiology of cirrhosis (No.)
Alcoholic 60
Viral 85
Others 10
Child-Pugh class A/B/C 31/88/36
No. (%) of patients with 
a previous bleeding episode 75 (48.4)
No. (%) with  spurting varices 27 (17.4)
Bilirubin (mg/dL) 3.1±4.4
Albumin (g/dL) 2.7±0.6
Prothrombin time (sec) 14.8±3.0
Characteristics Value
Table 1. Clinical characteristics of patients treated with trans-
jugular intrahepatic portosystemic shunt (TIPSS)
Survival
All (No.; 155) 66.6 58.4 38.1
Child-Pugh class
A 76.7 72.8 51.9
B 73.0 60.6 35.9
C 42.7 42.7 35.6
Age (yr)
≤39 92.3 83.1 72.7
40-49 65.2 59.0 34.2
50-59 71.3 64.4 46.7
60-69 63.0 52.0 22.5
≥70 23.3 11.7 11.7
Rebleeding 21.0 32.8 53.1
1 yr (%)   2 yr (%)   5 yr (%)
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Complications
Hepatic encephalopathy was the most common compli-
cations related to the TIPSS procedure. It developed as a
complication of TIPSS in 49 cases; it was newly developed
within 2 months after TIPSS or aggravated compared with
before TIPSS. Eighteen (36.7%) among 49 cases of hepatic
encephalopathy had chronic recurrent attacks; they experienced
the acute episode of hepatic encephalopathy more than twice
during hospitalization or over 3 times as out patients. 21 cases
(42.9%) among them showed the pattern of transient hepatic
encephalopathy.
In two cases (4.1%), hepatic encephalopathy was the major
cause of death. Eight patients expired due to hepatic failure
(Table 3).
Puncture of the bile duct developed during procedure in 19
cases, puncture to intraperitoneal space in 13 cases, infections
in 10 cases, distortions of the stent in 3 cases, and hemolysis
in 1 case. In 1 case of bile duct puncture, vascular embolization
was done due to hemobilia.
Causes of deaths
Among 86 patients who expired during follow-up after
TIPSS, hepatic failure was the most common cause of death
(46 patients, 53.5%). Rebleeding occurred in 14 cases (16.3%),
pneumonia in 4 cases (4.6%), hepatic encephalopathy in 2
cases (2.3%), sepsis in 3 cases (3.5%), renal failure in 1 case
(1.2%) and the cause of death was unknown in 16 cases (18.6%)
(Table 4).
DISCUSSION
About 30% of patients with liver cirrhosis have esophageal
varices, and about 30% of them are expected to experience
bleeding afterwards (11). The mortality rate of patients with
variceal bleeding due to liver cirrhosis is 30-50% (12). The
main therapeutic modalities include aggressive resuscitation,
continuous infusion of vasopressin, nitrate (13) or somatostatin
(14), endoscopic sclerotherapy, and band ligation (13, 15),
which are generally used for gastric or esophageal variceal
bleeding. In spite of this therapies, however, the 30-day survival
rate of the Child-Pugh classification C patients was no more
than 50% (13, 16). Surgical shunt operation could decrease
the portal pressure and treat the esophageal variceal bleeding,
however, the 30-day survival rate was no more than 50% in
emergent situations for controlling variceal bleeding in advanced
liver cirrhosis (16-18). 
In 1969, TIPSS, which could decrease the portal pressure
nonsurgically, was introduced after animal test results by
Rosch et al. (9), and then in 1988, it proved effective in
humans by using a metal stent (19). The purpose of TIPSS is
to increase survival of patients with liver cirrhosis through
reducing the portal pressure for stopping gastric or esophageal
variceal bleeding and preventing rebleeding. TIPSS is indi-
cated for cases where pharmacologic or endoscopic manage-
ment failed and the risk for surgical shunt operation is high.
Especially patients with variceal bleeding who are scheduled
for liver transplantation can be treated by TIPSS without
intraabdominal anatomical changes. In fact, by Ring et al. (20),
more than 50% of patients received liver transplantation
within 1 month after TIPSS. Recently, many studies showed
the effectiveness of TIPSS for pharmacologically nonrespon-
sive ascites of liver cirrhosis (21). TIPSS can be used for treat-
ment of Budd-Chiari syndrome or portal hypertension due
to portal vein thrombosis (22, 23). 
In previous studies (24-27), the technical success rate and
bleeding control rate of TIPSS were reported as 93-100% and
96-100%, respectively. The shunt was successfully established
in all 155 cases in this study. Several studies have shown that
gastric or esophageal varices recur or bleeding develop common-
ly when the portal pressure is higher than the inferior vena
caval (IVC) pressure by 12 mmHg (11, 28). In our study, the
portocaval pressure gradient was 20.5±9.93 mmHg before
TIPSS, 10.7±6.62 mmHg after TIPSS, showing on average
decrease of 9.8±5.54 mmHg. The results are consistent with
those from other studies (27, 29, 30). 
In a follow-up study of 90 variceal bleeding patients for 2.2
yr, the 1-yr survival rate was 60% and 2-yr survival rate was
51% (30). The present study showed that the 6-month survival
rate after TIPSS was 75.1%, 1-yr survival rate was 66.6%,
2-yr survival rate was 58.4%, and 5-yr survival rate was 38.1%.
Several studies have shown that the residual liver function
by the Child-Pugh classification was a more important factor
than the decrease in the portal pressure or portocaval venous
pressure gradient affecting the survival rate after TIPSS (29,
30). The present study showed that the survival time in the
group A according to the Child-Pugh classification was 225.0
Transient symptom 21 (42.9)
Chronic recurrent attack 18 (36.7)
Death due to hepatic encephalopathy 2 (4.1)
Death due to hepatic failure 8 (16.3)
Clinical outcome n=49 (%)
Table 3. Clinical outcome of the patients who developed hep-
atic encephalopathy after TIPSS
Hepatic failure 46 (53.5)
Rebleeding 14 (16.3)
Pneumonia 4 (4.6)
Sepsis 3 (3.5)
Hepatic encephalopathy 2 (2.3)
Renal failure 1 (1.2)
Unknown 16 (18.6)
Causes of death n=86 (%) 
Table 4. Causes of death after TIPSS776 Y.T. Kim, M.K. Jung, C.M. Cho, et al.
±27.6 weeks, the group B was 192.5±19.8 weeks and the
group C was 53.6±9.5 weeks (p<0.05). The age of patient at
the time of TIPSS was a statistically significant factor affect-
ing the survival time (p<0.0001). However, the etiology of
liver cirrhosis, sex, variceal grade, and the magnitude of
decrease in the portal vein pressure had no effect on survival.
One study showed that the rebleeding rate after TIPSS in
the first year was 26%, second year was 32%, and the aver-
age interval between TIPSS procedure and rebleeding was
6.8±6.2 months (30). The present study showed that the aver-
age interval between TIPSS procedure and rebleeding was
167.9±10.7 weeks. And the rebleeding rate after TIPSS was
18.3% in 6 months, 21% in the first year, 32.8% in the sec-
ond year and 53.1% in the fifth year. The Child-Pugh classifi-
cation did not affect the rebleeding rate significantly. 
In the present study, 50 cases experienced rebleeding. Twen-
ty-four among them underwent a second TIPSS, 8 patients
expired during resuscitation, 12 were treated by conservative
medical therapy, 4 received coil embolization and 2 received
band ligation. Six patients, after control of the first rebleeding
episode, eventually expired due to subsequent rebleeding.
In a follow-up study of 90 variceal bleeding patients by La
Berge et al. (30), 22 patients received a total of 30 procedures
of new stent insertion or angioplasty for shunt recanalization.
In the present study, 36 patients received a total of 50 proce-
dures for shunt stenosis, obstruction, or rebleeding. It was
suggested that the control of shunt stenosis is very helpful for
the improvement of survival. Williams et al. showed that all
rebleeding cases had shunt stenosis or obstruction (31). In
the present study, 43 out of 50 rebleeding cases underwent
duplex ultrasonography to check for the shunt patency, and
32 cases (74.4%) were shown to have shunt obstruction or
stenosis and 11 cases (25.6%) had an intact shunt. Rebleed-
ing after TIPSS was closely related with shunt obstruction.
Some researchers suggested that surgical shunt operation
would be better than TIPSS as a long term treatment modality
for gastric or esophageal variceal bleeding considering the high
rate of shunt obstruction (32). However, with careful follow-
up for shunt patency and timely correction of shunt stenosis
or obstruction, TIPSS was effective for the long-term bleed-
ing control.
Complications after TIPSS were encephalopathy, obstruction
of the shunt, rebleeding, transposition of the stent, hematoma
at the puncture site, rupture of liver capsule (33, 34), and rarely
intraabdominal bleeding (27) or hepatic infarction (35). In
this study, the most common complication after procedure
was hepatic encephalopathy. Hepatic encephalopathy that
developed newly or aggravated within 2 months after TIPSS
compared with before TIPSS was considered as a complication
of TIPSS. This was the case in 49 patients (31.6%). This obser-
vation was similar to the frequency of hepatic encephalopathy
after surgical shunt operation (20-50%) (36, 37). Eighteen
(36.7%) out of 49 cases were treated for hepatic encephalopathy
more than twice during hospitalization, or more than 3 times
in outpatient clinic. This was considered as a pattern of chronic
recurrent hepatic encephalopathy. Twenty-one (42.9%) showed
a transient hepatic encephalopathy pattern.
Hepatic encephalopathy was considered to be a direct cause
of death in 2 cases (4.1%) and 8 patients died of concurrent
hepatic failure. A previous study reported that the group C by
the Child-Pugh classification showed a higher frequency of
hepatic encephalopathy (38). In the present study, however, the
Child-Pugh classification was not significantly related with the
development of hepatic encephalopathy. Other complications
were biliary puncture in 19 cases and abdominal puncture
in 13 cases. Conservative management was successful in all
these cases. Infection occurred in 10 cases, transposition of
stent in 3 cases and hemolysis in 1 case. 
In summary, TIPSS is an effective method of treatment for
variceal bleeding in cases where other treatment modalities
including endoscopic therapy are unsuccessful and the most
important prognostic factors are the preprocedural hepatic
reserve (Child-Pugh class) and age. TIPSS by itself is not a
definite therapy, but in combination with careful follow-up
surveillance and shunt revision TIPSS is a very effective ther-
apeutic strategy for the control of variceal bleeding.
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